EP2007382A1 - Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren - Google Patents

Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren

Info

Publication number
EP2007382A1
EP2007382A1 EP07727387A EP07727387A EP2007382A1 EP 2007382 A1 EP2007382 A1 EP 2007382A1 EP 07727387 A EP07727387 A EP 07727387A EP 07727387 A EP07727387 A EP 07727387A EP 2007382 A1 EP2007382 A1 EP 2007382A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
cycloalkyl
aryl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07727387A
Other languages
German (de)
English (en)
French (fr)
Inventor
Steffen Breitfelder
Udo Maier
Christoph Hoenke
Anne T. Joergensen
Alexander Pautsch
Trixi Brandl
Matthias Grauert
Matthias Hoffmann
Stefan Scheuerer
Klaus Erb
Michael Pieper
Ingo Pragst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to EP07727387A priority Critical patent/EP2007382A1/de
Publication of EP2007382A1 publication Critical patent/EP2007382A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel thiazolyl-dihydro-cyclopentapyrazoles of the general formula (I)
  • radicals R 1 , R 2 , R a and R b have the meanings mentioned in the claims and the description, their tautomers, racemates, enantiomers, diastereomers and their mixtures, and optionally their pharmacologically acceptable acid addition salts, solvates and hydrates, and methods for the preparation of these thiazolyl-dihydro-cyclopentapyrazoles and their use as medicaments.
  • Phosphatidylinositol 3-kinases are a subfamily of lipid kinases that catalyze the transfer of a phosphate moiety to the 3 'position of the inositol ring of phosphoinositides.
  • PI3-kinases can be used in many tumors, such as breast cancer, ovarian or pancreatic carcinoma, tumor types such as colon, breast or lung carcinomas, but especially in autoimmune diseases such as Crohn's disease or rheumatoid arthritis, or in the cardiovascular system such for example, in the development of cardiac hypertrophy (Oudit et al., Circulation, 2003 Oct. 28; 108 (17): 2147-52).
  • PI3-kinase modulators may provide a potential for anti-inflammatory therapy with relatively minor side effects (Ward and Finan, Curr Opin Pharmacol., 2003 Aug; 3 (4): 426-34).
  • PI3-kinase inhibitors for the treatment of inflammatory diseases are known in the literature.
  • WO 03/072557 discloses 5-phenylthiazole derivatives
  • WO 04/029055 shows anellated azolpyrimidines
  • WO 04/007491 azolidinone-vinyl-linked benzene derivatives.
  • the two documents WO 04/052373 and WO 04/056820 disclose benzoxazine and benzoxazin-3-one derivatives.
  • the object of the present invention is to provide novel compounds which, owing to their pharmaceutical activity, can be used as a PI3-kinase modulator for therapeutic use in the treatment of inflammatory or allergic diseases.
  • inflammatory and allergic respiratory disorders are inflammatory and allergic respiratory disorders, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions, in which autoimmune reactions are involved or called kidney inflammations.
  • compounds of the formula (I) act as inhibitors of PI3-kinase, in particular as inhibitors of PI3-kinase gamma.
  • the compounds according to the invention can be used, for example, for the treatment of respiratory diseases.
  • the present invention therefore relates to compounds of the general formula (I),
  • R a is hydrogen or an optionally substituted radical selected from
  • R b is hydrogen, NH 2 or OH, or an optionally substituted radical selected from the group consisting of Ci-C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl , C 3 -C 8 cycloalkenyl, C r
  • Ce-haloalkyl C 6 -C 4 aryl, C 6 -C 4 -alkyl- aryl-Ci-C 5, C 5 -C 0 heteroaryl, C 3 -C 8 - cycloalkyl-C r C 4 alkyl -, C 3 -C 8 cycloalkenyl-C r C 4 alkyl, C 5 -C 0 -heteroaryl-Ci-C 4 - alkyl, C 9 -C 3 spiro, C 3 -C 8 heterocycloalkyl, CONH 2 , C 6 -C 4 -aryl-NH-, C 3 -C 8 -heterocycloalkyl-NH- and OMe,
  • R 1 is hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl and C 6 -C 4 -aryl -Ci-C 5 alkyl
  • R 2 is hydrogen or an optionally substituted radical selected from the group consisting of C r C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkenyl, C r C 6 haloalkyl , C 4 -C 6 aryl, C 6 -C 4 -alkyl- aryl-Ci-C 5, C 5 -C 0 - heteroaryl, C 3 -C 8 cycloalkyl-Ci-C 4 alkyl, C 3 -C 8 -cycloalkenyl-C
  • R 1 and R 2 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen.
  • R 1 and R 2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring
  • R 2 is a radical selected from the group consisting of the general
  • X is a bond or an optionally substituted radical selected from among
  • X together with R 1 , R 3 or R 4 can form a C 1 -C 7 -alkylene bridge;
  • Y is a bond or optionally substituted C 1 -C 4 -alkylene;
  • Q is an optionally substituted radical selected from the group consisting of C r C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene,
  • R 3 , R 4 , R 5 are identical or different, hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 6 -alkyl, C 3 -C 8 -
  • R 3 , R 4 , R 5 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
  • G is a saturated, partially saturated or unsaturated ring system of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
  • R 7, R 8, R 9 are identical or different, represent hydrogen or an optionally substituted radical selected from the group consisting of -C 8 alkyl, C 3 -C 8 - cycloalkyl, C 2 -C 6 haloalkyl, Ci-C4- -Alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-dC 3 -alkyl-, C 6 -C 4 -aryl, C 1 -C 4 -alkyl-C 6 -C 4 -aryl-, C 6 -C 4 -aryl-C 1 -C 4 -alkyl, C 1 -C 6 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -
  • R 7 , R 8 , R 9 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
  • X, Y, Q and G may have the meaning given, and
  • R a is hydrogen or a radical selected from the group consisting of -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, C r C 6 - haloalkyl, C 6 -C 4 -Ar / !, Ce-Cu-aryl-CRCS alkyl, C 5 -C 0 heteroaryl, C 3 -C 8 -
  • R 10 , R 11 , R 12 are identical or different, hydrogen or a radical selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 - Cycloalkyl and C r C 6 haloalkyl; or in each case two of the radicals
  • R 10 , R 11 , R 12 together form a five, six or seven membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
  • R b is hydrogen, NH 2 or OH, or an optionally substituted radical selected from the group consisting of d-C ⁇ -alkyl, C 3 -C ⁇ cycloalkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkenyl, C r
  • Ce-haloalkyl C 6 -C 4 aryl, Ce-Cu-aryl-Ci-Cs-alkyl, C 5 -C 0 heteroaryl, C 3 -C 8 - cycloalkyl-C r C 4 alkyl, C 3 -C 8 cycloalkenyl-Ci-C 4 alkyl, C 5 -C 0 -heteroaryl-Ci-C 4 - alkyl, C 9 -C 3 spiro, C 3 -C 8 heterocycloalkyl, CONH 2, C 6 -C 4 -aryl-NH-, C 3 -C 8 -heterocycloalkyl-NH- and OMe which may contain one or more of the radicals, identical or different, selected from the group consisting of
  • Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C r C 6 haloalkyl, halogen, OH, OMe, CN, NH 2, NHMe and NMe 2, may be substituted;
  • R 1 is hydrogen or a radical selected from the group consisting of -C 8 alkyl, C 3 -C ⁇ cycloalkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, and C 6 -C 4 aryl-Ci C 5 alkyl optionally having one or more of the same or different radicals selected from the group consisting of halogen, NH 2 , OH, CN, C 1 -C 6 alkyl, OMe, -NH (CO) alkyl and - (CO) O-alkyl may be substituted,
  • R 2 is hydrogen or a radical selected from the group consisting of -C 8 alkyl, C 3 -C ⁇ cycloalkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkenyl, C r C 6 haloalkyl, C 6 - Ci 4 -aryl, C 6 -C 4 aryl-Ci-C 5 alkyl, C 5 -C 0 heteroaryl, C 3 -C 8 cycloalkyl-alkyl- C r C 4, C 3 -C 8 - cycloalkenyl -C 4 alkyl, Cs-Cio-heteroaryl-Ci-C ⁇ -alkyl, C 9 -C 3 spiro, C 3 -C 8 - heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-CrC 6 alkyl - and Ce-C M -aryl-Ci-C ⁇ -alkyl
  • R 1 and R 2 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, optionally with one or more of the radicals, the same or different selected from the group consisting of heterocycles loalkyl, halogen, NH 2, OH, CN, C r C 6 alkyl, OMe, -NH (CO) -alkyl, and -
  • R 1 and R 2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring
  • R 2 is a radical selected from the group consisting of the general
  • R 3 , R 4 , R 5 are identical or different, are hydrogen or a radical selected from the group consisting of C 1 -C 6 -alkyl, C 5 -C 6 -cycloalkyl, C 2 -C 6 -haloalkyl,
  • R 3 , R 4 , R 5 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; which may optionally be substituted by one or more of the radicals, identical or different, selected from the group consisting of halogen, NH 2 , OH, CN, NR 9 R 10 , -NH (CO) -CrC 4 -AlkVl and MeO,
  • R 6 is identical or different, hydrogen or a radical selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 6 - Ci 4 -aryl, C 5 -C 0 heteroaryl and C 3 -C 8 -heterocycloalkyl, optionally substituted by one or more of the radicals, the same or different, selected from the group consisting of, NH 2, NHMe, NMe 2 OH, OMe, CN, -Ci-C 3 -alkyl-C 6 -C 4 -
  • Aryl, -NH-CO-NH-d-Cs-alkyl, and C r C 6 alkyl, - (CO) OC r C 6 alkyl, or a radical selected from the group consisting of O, NR 7 R 8, OR 7, -CO-CrC 3 - alkyl-NR 7 R 8 -O-Ci-C 3 alkyl-NR 7 R 8, CONR 7 R 8, NR 7 COR 8, CO-C r C 3- alkyl
  • NR 7 (CO) OR 8 -O (CO) NR 7 R 8 , NR 7 (CO) NR 8 R 9 , NR 7 (CO) OR 8 , (CO) OR 7 , -O (CO) R 7 , COR 7 , (SO) R 7 , (SO 2 ) R 7 , (SO 2 ) NR 7 R 8 , NR 7 (SO 2 ) R 8 , NR 7 (SO 2 ) NR 8 R 9 , CN and halogen;
  • R 7 , R 8 , R 9 are identical or different, hydrogen or a radical selected from the group consisting of C r C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 haloalkyl, C r C 4 Alkyl C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C r C 3 alkyl, C 6 -C 4 aryl, C r C 4 alkyl C 6 -C 4 aryl -, C 6 -C 4 -aryl-C 1 -C 4 -alkyl-, C 3 -C 8 -heterocycloalkyl, C r C 5 -
  • R 7 , R 8 , R 9 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; optionally with one or more of the radicals, identically or differently, selected from the group consisting of halogen, NH 2 , OH, CN, OMe, NHMe, NMe 2 C r C 6 alkyl and (CO) OC r C 6 alkyl , may be substituted.
  • R a and R 1 to R 12 may have the meaning given, and
  • R b is hydrogen
  • R a C 6 -C 4 -aryl or a saturated ring system of 5-6 C atoms, wherein optionally up to 4 C atoms are replaced by nitrogen atoms, wherein R a is optionally selected with one or more of the radicals, identical or different from the group consisting of d-C ⁇ -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C r C 6 haloalkyl, halogen, OH, Ci-C4- Alkoxy, CN, NO 2 , NR 10 R 11 , OR 10 , COR 10 , COOR 10 , CONR 10 R 11 , NR 10 COR 11 , NR 10 (CO) NR 11 R 12 , 0 (CO) NR 10 R 11 , NR 10 (CO) OR 11 , SO 2 R 10 , SOR 10 , SO 2 NR 10 R 11 , NR 10 SO 2 NR 11
  • R b is hydrogen, NH 2 or OH, or a radical selected from the group consisting of QrC ⁇ -cycloalkyl, Ce-Ci 4 -aryl, C 5 -Cio-heteroaryl, C 6 -C 4 -aryl-NH-, C r C 8 -alkyl, C 2 -C 8 Alkenyl, C 2 -C 8 alkynyl and C 1 -C 6 haloalkyl, optionally with one or more of the radicals, the same or different, selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C r C 6 haloalkyl, halo, OH, OMe, CN, NH 2 , NHMe and NMe 2 ; mean.
  • R 1 is hydrogen, C r C 5 alkyl or C 3 -C 8 -CyCl oa I ky I,
  • R 2 is hydrogen, C r C 5 alkyl or C 3 -C 8 cycloalkyl
  • R 1 and R 2 together form an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1 to 2 nitrogen atoms, or
  • R 1 and R 2 together form an optionally substituted nine- to thirteen-membered spirocyclic ring
  • R 1 , R 2 are identical or different, a radical selected from the group consisting of the general formulas (A2), (A3), (A8), (A10), (A11) and (A12), wherein
  • X is a bond or an optionally substituted CrC 3 -alkylene, or
  • X together with R 1 , R 3 or R 4 can form a 5- or 6-membered heterocycle
  • Q is an optionally substituted C 1 -C 3 -alkylene, or Q together with R 1 , R 3 or R 4 can form a C 1 -C 7 -alkylene bridge;
  • R 3 , R 4 , R 5 are identical or different, hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -
  • R 3 , R 4 , R 5 together form an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen and nitrogen; mean.
  • R 2 is hydrogen or a radical of the general formulas (A18), where
  • X is a bond or an optionally substituted radical selected from the group consisting of -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 alkynylene, or
  • X together with R 1 can form a CrC 7 -alkylene bridge;
  • Y is a bond or methylene, ethylene;
  • X and Y may be linked to the same or different atoms of G, and
  • G is a saturated, partially saturated or unsaturated ring system of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
  • R 7 , R 8 , R 9 are identical or different, hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 5 -alkyl, C 1 -C 4 -alkyl
  • Heteroatoms selected from the group consisting of oxygen and
  • Nitrogen mean.
  • Another object of the invention are compounds of formula (I) for use as medicaments.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of diseases in their Pa an activity of PI3-kinases is involved, in which therapeutically effective doses of the compounds of formula (I) can develop a therapeutic benefit.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of inflammatory and allergic diseases of the respiratory tract.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of chronic bronchitis, acute bronchitis, bronchitis due to bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive pulmonary disease (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or cystic fibrosis, alpha-1-antitrypsin Deficiency, cough, pulmonary emphysema, interstitial lung disease, alveolitis, hyperreactive airways, nasal polyps, pulmonary edema, pneumonitis due to differential causes such as radiation-induced or by aspiration or infectious, collagenoses such as lupus erythematosus, system
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of inflammatory and allergic diseases of the skin.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exudative multiforme (Stevens-Johnson syndrome), dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria), lupus erythematosus, follicular and areal pyoderma, endogenous and exogenous acne, acne rosacea, and other inflammatory and allergic or proliferative skin diseases.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of inflammation of the eye
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of conjunctivitis of various Species such as fungal or bacterial infections, allergic conjunctivitis, irritable conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis.
  • a disease selected from the group consisting of conjunctivitis of various Species such as fungal or bacterial infections, allergic conjunctivitis, irritable conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis.
  • Another object of the invention is the use of the compounds of formula (I), for the manufacture of a medicament for the treatment of diseases of the nasal mucosa.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of allergic rhinitis, allergic sinusitis and nasal polyps.
  • Another object of the invention is the use of the compounds of formula (I), for the manufacture of a medicament for the treatment of inflammatory or allergic disease states, in which autoimmune reactions are involved.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic hepatitis, multiple sclerosis, rheumatoid Arthritis, psoriatic arthritis, osteoarthritis, rheumatoid spondylitis.
  • a disease selected from the group consisting of Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic hepatitis, multiple sclerosis, rheumatoid Arthritis, psoriatic arthritis, osteoarthritis, rheumatoid spondylitis.
  • Another object of the invention is the use of the compounds of formula (I), for the manufacture of a medicament for the treatment of renal inflammation.
  • Another object of the invention is the use of the compounds of formula (I) for the manufacture of a medicament for the treatment of a disease selected from the group consisting of glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome.
  • a pharmaceutical formulation comprising a compound of the formula (I).
  • an orally administrable pharmaceutical formulation comprising a compound of the formula (I).
  • Alkyl groups and alkyl groups which are part of other groups are branched and unbranched alkyl groups having 1 to 10 carbon atoms, preferably 1 to 6, particularly preferably 1 to 4 carbon atoms, for example: methyl, ethyl, propyl, butyl, pentyl, hexyl , Heptyl, octyl, nonyl and decyl. Unless otherwise stated, of the above designations, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl include all of the possible isomeric forms.
  • propyl includes the two isomeric radicals n-propyl and iso-propyl, the term butyl n-butyl, iso-butyl, sec. Butyl and tert. Butyl, the term pentyl, iso-pentyl, neopentyl, etc.
  • one or more hydrogen atoms may be replaced by other radicals.
  • these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
  • the substituents are preferably fluorine or chlorine.
  • all hydrogen atoms of the alkyl group may also be replaced.
  • the alkyl bridge used is branched and unbranched 2-membered alkyl groups having 4 to 7 carbon atoms, for example, n-butylene, isobutylene, sec. Butylene and tert-butylene, pentylene, isopentylene, neopentylene, etc Designates bridges. Particularly preferred are n-butylene or n-pentylene bridges. In the abovementioned alkyl bridges, optionally 1 to 2 C atoms may be replaced by one or more heteroatoms selected from the group consisting of oxygen or sulfur.
  • d- 6 -alkylene (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 understood to 6 carbon atoms and by the term “C- ⁇ - 4 alkylene” are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms understood. Preferred are alkylene groups having 1 to 4 carbon atoms. Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene, pentylene, 1, 1-dimethylpropylene, 2,2, -dimethylpropylene, 1, 2-dimethylpropylene, 1, 3-dimethylpropylene or hexylene.
  • propylene, butylene, pentylene and hexylene include all conceivable isomeric forms of the respective radicals of the same carbon number.
  • propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene.
  • Alkenyl groups include branched and unbranched alkenyl groups having 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, more preferably 2 to 3 carbon atoms, provided they have at least one double bond. Examples which may be mentioned are: ethenyl, propenyl, butenyl, pentenyl, etc.
  • alkenyl groups one or more hydrogen atoms may optionally be replaced by other groups.
  • these alkenyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
  • the substituents are fluorine and chlorine. If appropriate, all hydrogen atoms of the alkenyl group may also be replaced.
  • C 2 - 6 alkenylene (including those which are part of other radicals) are branched and unbranched alkenylene groups having 2 to 6 carbon atoms and the term “C 2 - 4 alkenylene” branched and unbranched alkylene groups with 2 to 4 carbon atoms understood. Alkenylene groups having 2 to 4 carbon atoms are preferred.
  • Examples include: ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1, 1-dimethylethenylene, 1, 2-dimethylethenylene, pentenylene, 1, 1-dimethylpropenylene, 2,2-dimethylpropenylene, 1, 2-dimethylpropenylene, 1, 3-dimethylpropenylene or hexenylene.
  • propenylene, butenylene, pentenylene and hexenylene include all conceivable isomeric forms of the respective radicals of equal carbon number.
  • propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 1, 1-dimethylethenylene, 1, 2-dimethylethenylene.
  • Alkynyl groups are branched and unbranched alkynyl groups having 2 to 10 carbon atoms, provided they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
  • alkynyl groups having 2 to 4 carbon atoms examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • propynyl includes 1-propynyl and 2-propynyl
  • butinyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl, etc.
  • one or more hydrogen atoms in the abovementioned alkynyl groups may optionally be replaced by other radicals.
  • these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
  • the substituents are fluorine and chlorine.
  • all hydrogen atoms of the alkynyl group may also be replaced.
  • C 2 - 6 alkynylene (including those which are part of other groups) are meant branched and unbranched alkynylene groups with 2 to 6 carbon atoms understood and the term “C 2-4 alkynylene” are meant branched and unbranched Alkylengrup- understood pen with 2 to 4 carbon atoms. Alkynylene groups having 2 to 4 carbon atoms are preferred.
  • Examples include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1, 1-dimethylethynylene, 1, 2-dimethylethynylene, pentynylene, 1, 1-dimethylpropynylene, 2,2-dimethylpropynylene, 1, 2 Dimethylpropynylene, 1, 3-dimethylpropynylene or hexynylene.
  • the definitions propynylene, butynylene, pentynylene and hexynylene include all conceivable isomeric forms of the respective radicals of the same carbon number.
  • propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1, 1-dimethylethynylene, 1, 2-dimethylethynylene.
  • Cycloalkyl radicals are saturated cycloalkyl radicals having 3-8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, where any of the above optionally mentioned cycloalkyl radicals may carry one or more substituents or may be fused to a benzene ring.
  • cycloalkyl radicals can form, in addition to monocyclic, bicyclic, bridged or spirocyclic ring systems.
  • Cycloalkenyl are cyclic alkyl groups having 5 to 8, preferably 5 or 6, carbon atoms which contain one or two double bonds. Examples include: cyclopenttenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl or cyclooctadienyl.
  • the cycloalkenyl radicals can form, in addition to monocyclic radicals, bicyclic, bridged or spirocyclic ring systems.
  • cycloalkynyl (including those which are part of other radicals) are meant cyclic alkyl groups having 5 to 8, preferably 5 or 6, carbon atoms which contain one or two triple bonds. Examples include: cyclopentynyl, cyclopentadinyl, cyclohexynyl, cyclohexadinyl, cycloheptinyl, cycloheptadiynyl, cyclooctynyl or cyclooctadinyl.
  • the cycloalkynyl radicals can also form bicyclic, bridged or spirocyclic ring systems in addition to monocyclic compounds.
  • haloalkyl including those which are part of other radicals
  • haloalkyl are branched and unbranched alkyl groups having 1 to 6 carbon atoms, in which one or more hydrogen atoms by a halogen atom selected from the group fluorine, chlorine or bromine, preferably fluorine and chlorine, are exchanged.
  • a halogen atom selected from the group fluorine, chlorine or bromine, preferably fluorine and chlorine
  • Ci- 4 haloalkyl denotes branched and unbranched alkyl groups having 1 to 4 carbon atoms understood, in which analog described above, one or more hydrogen atoms are replaced.
  • CH 2 F, CHF 2 , CF 3 Preference is given to d- 4- haloalkyl.
  • aryl represents an aromatic ring system having 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, for example phenyl or naphthyl, preferably phenyl, which, unless otherwise specified, may carry, for example, one or more substituents. Further, any of the above-mentioned aryl systems may be optionally fused to a heterocycloalkyl group or a cycloalkyl group. Examples are: 2,3-dihydro-benzo [1,4] dioxin, benzo [1,3] dioxole, 1,2,3,4-tetrahydro-naphthalene and 3,4-dihydro-1H-quinoline. 2-one.
  • heterocycloalkyl radicals are, unless otherwise specified in the definitions, 5-, 6- or 7-membered, saturated or unsaturated, mono- or bicyclic heterocycles in which up to four carbon atoms by one or more hetero atoms selected from May be replaced by oxygen, nitrogen or sulfur, for example tetrahydrofuran, tetrahydrofuranone, ⁇ -butylrolactone, ⁇ -pyran, ⁇ -pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, Pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxa
  • a heterocyclic ring may be provided with a keto group. As an example for this are called.
  • Examples of 5-10-membered bicyclic heterorings are pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyridine,
  • heteroaryl 5-10-membered mono- or bicyclic heteroaryl rings in which up to three carbon atoms by one or more hetero atoms selected from the group oxygen, nitrogen or sulfur may be replaced, these containing so many conjugated double bonds in that an aromatic system is formed.
  • Each of the above heterocycles may optionally be further fused to a benzene ring.
  • fused heteroaryl radicals are: Benzimidazole, indole and pyrimidopyrimidine.
  • each of the above-mentioned heterocycles may be optionally fused to a heterocycloalkyl group or a cycloalkyl group.
  • heteroaryl rings may, for example, carry one or more substituents, preferably halogen or methyl.
  • the ring may be linked to the molecule via a carbon atom or, if present, via a nitrogen atom.
  • five- or six-membered heterocyclic aromatic compounds there are mentioned:
  • Examples of 5-10 membered bicyclic heteroaryl rings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine.
  • heterocyclic spiro rings is understood to mean 5-13 membered, preferably 9-10-membered, spirocyclic rings which may optionally contain one, two or three heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, in which case the ring be linked to the molecule via a carbon atom or, if present, via a nitrogen atom.
  • a spiro-cyclic ring may be provided with a keto group.
  • the term "optionally substituted” in the context of the invention means the named group which is optionally substituted by a lower-molecular radical.
  • Low-molecular radicals are understood to be chemically meaningful groups consisting of 1-200 atoms. Preferably, such groups have no negative effect on the pharmacological activity of the compounds.
  • the groups may include:
  • Aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms, which in turn may be substituted with functional groups.
  • a plurality of aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms, which may be linked by one or more carbon chains, optionally interrupted by heteroatoms, optionally substituted with heteroatoms or other common functional groups.
  • the halogen is generally fluorine, chlorine, bromine or iodine.
  • the compounds of the invention may be in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of tautomers and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as, for example, oxalic, fumaric, diglycolic or methanesulfonic acid.
  • hydrohalic acids for example hydrochloric or hydrobromic acid
  • organic acids such as, for example, oxalic, fumaric, diglycolic or methanesulfonic acid.
  • the substituent R a may be hydrogen or an optionally substituted radical selected from the group consisting of -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 - cycloalkyl, C 3 -C 8 cycloalkenyl, C r C 6 haloalkyl, C 6 -C 4 aryl, Ce-Cu-aryl-CRCS alkyl, C 5 - Cio-heteroaryl, C 3 -C 8 cycloalkyl-Ci-C 4 - alkyl-, C 3 -C 8 alkyl cycloalkenyl-Ci-C 4, C 5 -C 0 - alkyl- heteroaryl Ci-C 4, C 9 -C 3 spiro, C 3 -C 8 -heterocycloalkyl and C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -alkyl
  • NR 10 SO 2 NR 11 R 12 and NR 10 SO 2 R 11 preferably C r C 6 haloalkyl, halogen and CONR10R 11 , particularly preferably CF 3 , F, Cl, Br and CONHCH 3 , may be substituted. More preferably R a is phenyl optionally substituted with one or more of the radicals selected from the group consisting of CF 3 , F, Cl, Br and CONHCH 3 .
  • the substituents R 10 , R 11 , R 12, identical or different, may be hydrogen or a radical selected from the group consisting of the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl , C 3 -C 8 cycloalkyl and C r C 6 haloalkyl; or in each case two of the radicals
  • R 10 , R 11 , R 12 together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen.
  • the substituent R b may be hydrogen, NH 2 or OH, or an optionally substituted radical selected from the group consisting of CrC 8 -
  • R b is preferably hydrogen, NH 2 or OH, or a radical selected from the group consisting of C 3 -C 8 -cycloalkyl I ky I, C 6 -C 4 -aryl, C 5 -C 10 -heteroaryl, C 6 - Ci 4-aryl-NH-, C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C r C 6 halo- alkyl, optionally substituted with one or more of the radicals, the same or different, selected from the group consisting of Ci-C ⁇ alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 - cycloalkyl, C r C 6 haloalkyl, halogen, OH, OMe , CN, NH 2 , NHMe and NMe 2 may be substituted.
  • R b is hydrogen
  • the substituent R 1 may represent hydrogen or an optionally substituted radical selected from the group consisting of dC 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkenyl, C 2 -C 8 - alkynyl, and C ⁇ -C M -Aryl-CrCs-alkyl- mean.
  • R 1 is hydrogen, C 1 -C 5 -alkyl or C 3 -C 8 -cycloalkyl.
  • the substituent R 1 is hydrogen or a radical selected from the group consisting of methyl, ethyl, propyl, cyclopropyl and piperidine, more preferably R 1 is hydrogen or methyl.
  • the substituent R 1 may preferably have one or more of the radicals, identical or different, selected from the group consisting of halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, -NH (CO) alkyl and - ( CO) OC r C 4 alkyl substituted.
  • the substituent R 2 may represent hydrogen or an optionally substituted radical selected from the group consisting of -C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkenyl, C r C 6 - Haloalkyl, C 6 -C 4 -Ar / !, Ce-Cu-arylCrCs-alkyl, C 5 -Ci 0 - Heteroaryl, alkyl C 3 -C 8 cycloalkyl-C 4, C 3 -C 8 cycloalkenyl alkyl-Ci-C 4, C 5 -C 0 - heteroaryl-CrC 6 alkyl, C 9 -C 3 -spiro, C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-d-C 6 -alkyl and Ce-C m -aryl-
  • R 2 is preferably hydrogen or a radical selected from the group consisting of C 1 -C 5 -alkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 6 -C 4 -aryl-C 1 -C 5 -alkyl, C 3 -C 8 -heterocycloalkyl-C r C 6 -alkyl- and C 5 -Ci 0 -
  • R 2 is hydrogen or a radical selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, -CH 2 -C 3 -C 6 - cycloalkyl, -CH 2 -phenyl, -CH ⁇ Cs-Ce Heteroaryl and -CH 2 - C 3 -C 6 -heterocycloalkyl.
  • the substituent R 2 can preferably be selected from the group consisting of halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, -NH (CO) alkyl and - ( CO) OC r C 4 alkyl substituted.
  • the substituents R 1 and R 2 may together form an optionally substituted, five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, preferably nitrogen.
  • the group NR 1 R 2 particularly preferably represents an optionally substituted pyrrolidinyl radical.
  • the ring formed from the substituents R 1 and R 2 may preferably with one or more of the radicals, the same or different, selected from the group consisting of heterocycloalkyl, halogen, NH 2, OH, CN, C r C 6 alkyl, OMe, -NH (CO) alkyl and - (CO) O-C 1 -C 4 -alkyl.
  • the substituents R 1 and R 2 may together form an optionally substituted nine- to thirteen-membered spirocyclic ring, preferably
  • the substituent R 2 may further be a group selected from the group consisting of the general formulas (A1) to (A18) preferably (A1), (A10), (A11) and (A18).
  • X and Y may be linked to the same or different G atoms.
  • X may be a bond or an optionally substituted radical selected from the group consisting of C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, preferably a bond, methyl, ethyl and propyl, particularly preferably one Bond or methyl.
  • R 1 , R 3 or R 4 may together with R 1 , R 3 or R 4 form a 5- or 6-membered heterocycle, more preferably form a piperidinone or pyrrolidine ring with R 3 or R 4 , which may optionally be substituted.
  • the substituent R 1 and X preferably form a pyrrolidine or piperidine radical.
  • Y may be a bond or optionally substituted C 1 -C 4 -alkylene, preferably a bond, methylene or ethylene.
  • Q may be an optionally substituted radical selected from the group consisting of C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, preferably optionally substituted C 1 -C 3 -alkylene, particularly preferably ethyl and propyl.
  • Q may together with R 1 , R 3 or R 4 form a CrC 7 -alkylene bridge.
  • the substituents R 3 , R 4 , R 5 may be identical or different, hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -haloalkyl , Ci-C 4 alkyl-C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C r C 4 - alkyl, NR 7 R 8, NR 7 R 8 -C r C 4 alkyl , C r C 4 alkoxy, Ci-C 4 -alkoxy-C r C 4 alkyl, C 6 D 4 aryl and C 5 -C 0 -heteroaryl; preferably hydrogen or an optionally substituted radical selected from the group consisting of -C 4 alkyl, dC 4 alkoxy and C 3 -Ce- cycloalkyl, more preferably hydrogen, methyl, methoxy,
  • substituents R 3 , R 4 , R 5 may together form an optionally substituted five-, six- or seven-membered ring, preferably 5- or 6- a membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; preferably from oxygen or nitrogen.
  • the radical NR 3 R 4 preferably denotes pyrrolidinone or dihydroimidazolidinone.
  • the substituents R 3 , R 4 , R 5 or the ring formed therefrom may preferably contain one or more of the radicals, identically or differently, selected from the group consisting of halogen, NH 2 , OH, CN, NR 9 R 10 , -NH (CO) -C r C 4 alkyl and MeO be substituted.
  • G may represent a saturated, partially saturated or unsaturated ring system of 3-10 C atoms, wherein optionally up to 4 C atoms are replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • G may preferably be a saturated, partially saturated or unsaturated ring system of 3-8 C atoms, more preferably of 5-6 C atoms, in which optionally up to 6 C atoms, particularly preferably up to 4 C atoms, by heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur, are replaced.
  • G is preferably a ring system consisting of one or two 5-6 membered rings, more preferably selected from the group consisting of cyclohexyl, phenyl, pyrrolidine, piperidine, piperazine, pyrazole, pyridine, imidazole, thiazole, triazole, oxazole, oxadiazole , Tetrazole, benzimidazole, benzopyrrole and dihydrobenzo [1, 4] dioxins, particularly preferably benzimidazole, cyclohexyl, phenyl, pyrrolidine, piperidine, pyrazole, imidazole, thiazole, oxazole, oxadiazole and tetrazole.
  • the substituent R 6 may be the same or different, is hydrogen or an optionally substituted radical selected from the group consisting of, -C 8 alkyl, C 2 -C 6 - alkenyl, C 3 -C 8 cycloalkyl, C 2 -C 6 haloalkyl, C 6 -C 4 aryl, C 5 -C 0 heteroaryl and C 3 -C 8 - heterocycloalkyl, preferably hydrogen or an optionally substituted radical selected from the group consisting of dC 4 alkyl, C 3 -C 6 -cycloalkyl, C 6 -C 4 -aryl, C 5 -C 6 -heterocycloalkyl, and C 5 -C 6 -heteroaryl, more preferably hydrogen or an optionally substituted radical selected from the group consisting of C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 5 -C 6 -heterocycloalkyl
  • the substituent R 6 can preferably have one or more of the radicals, identical or different, selected from the group consisting of NH 2 , NHMe, NMe 2 OH, OMe, CN, -Ci-C 3 -alkyl-C 6 -C 4 - Aryl, -NH-CO-N HC r C 3 alkyl and - (CO) OC r C 4 alkyl substituted be-iert.
  • n is 1, 2 or 3, preferably 1 or 2, more preferably 1.
  • R 7, R 8, R 9 may be the same or different, is hydrogen or where appropriate substituted radical selected from the group consisting of -C 8 alkyl, C 3 - Cs-cycloalkyl, C r C 6 haloalkyl, C r C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C r C 3 -alkyl, C 6 -C 4 -aryl, C 1 -C 4 -alkyl-C 6 -C 4 - aryl, C 6 -C 4 -aryl-C 1 -C 4 -alkyl, C 3 -C 8 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-dC 4 -alkyl-, C r C 4 alkyl (
  • R 7 , R 8 , R 9 together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1-2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, preferably an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1-2 Heteroatoms selected from the group consisting of oxygen and nitrogen; especially preferably nitrogen.
  • the substituents R 7 , R 8 , R 9 or the ring system formed therefrom can preferably with one or more of the radicals, identically or differently, selected from the group consisting of halogen, NH 2 , OH, CN, OMe, NHMe, NMe 2 C R C 6 alkyl and (CO) OC r C 6 alkyl substituted.
  • intermediate compound (IV) is obtained.
  • a suitable base for example, but not limited to the group sodium methylate, Sodium ethylate, lithium hexamethylsilazide sodium hydride with a suitable acylating reagent (V) in the intermediate compound (VI) are transferred.
  • R b has the meanings given above.
  • R z is a suitable leaving group selected, for example, from but not limited to the group halogen, S-alkyl, S-aryl, O-alkylsulfonyl, O-arylsulfonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O -Aryl, wherein O-aryl may optionally be substituted by suitable electron-withdrawing groups (eg nitro).
  • a suitable hydrazine (VII) or one of its salts the intermediate compound (VIII) is obtained.
  • R a has the meanings given above.
  • the compound thus obtained is then converted into the free aminothiazole (IX) by cleavage of the acetyl group (for example by acidic or basic saponification or reaction with hydrazine hydrate).
  • the conversion to the ureas of the general formula (I) or (Ia) is then carried out using one of the following methods: Direct reaction with a suitable isocyanate (XIII) leads directly to compounds of the formula (Ia).
  • Reaction with a suitable reagent (XIV) leads to compounds of the formula (I) where R x is selected from a suitable leaving group, for example from but not limited to the group halogen, S-alkyl, S-aryl, O-alkylsulfonyl, O-arylsulfonyl, O-alkyl, imizazole, O-hetaryl, O-acyl, O-aryl, wherein O-aryl may optionally be substituted by suitable electron-withdrawing groups (eg nitro).
  • Another possibility is the reaction of the aminothiazole (IX) with a reagent of the general formula (X) to form an activated intermediate compound (XI).
  • R x and R y are the same or different suitable leaving groups selected for example from, but not limited to the group halogen, S-alkyl, S-aryl, O-alkylsulfonyl, O-arylsulfonyl, O-alkyl, imizazole, O-hetaryl , O-acyl, O-aryl, where O-aryl may optionally be substituted by suitable electron-withdrawing groups (eg nitro).
  • the intermediate compound (XI) may be in equilibrium with the isocyanate (XII) which may be formed by elimination of the leaving group R y (XI).
  • the further reaction of the intermediate compound (XI), (XII) or a mixture of both with suitable amines of the general formula (XV) leads to the desired compounds of the general formula (I).
  • R 1 and R 2 have the meanings given above.
  • Reagents of the general formula (XIX) can be prepared as follows: The reaction of a reagent of the general formula (XVI) with a hydrazine of the general formula (XVII) gives the intermediate compound (XVIII).
  • Rv is a suitable leaving group selected, for example, from but not limited to the group halogen, S-alkyl, S-aryl, aryl-sulfonyl, alkyl-sulfonyk PG1 and PG2 are different (orthogonal) suitable amine protecting groups selected, for example, from but not limited to the group alkylcarbonyl (carbamates), phthalimides, benzyl (optionally substituted, for example, p-methoxybenzyl).
  • pyrazolones of the general formula (Id) can be obtained by reacting the intermediate compound (XXI) with beta-ketoesters of the formula (XXIV).
  • Y and R6 have the meanings given above.
  • Rw is an alkyl group.
  • an intermediate of the general formula (XXVI) By reacting a reagent of the general formula (XXV) with the above-described intermediate compound (IX), an intermediate of the general formula (XXVI) can be obtained.
  • R s is a radical selected, for example, from but not limited to the group alkyl, aryl.
  • Reaction of the thus obtained intermediate compound (XXVI) with acetonitrile, which was previously deprotonated by a suitable base (eg n-butyllithium) affords the beta-ketonitrile compound (XXVII).
  • a suitable base eg n-butyllithium
  • aminopyrazoles of the general formula (Ie) are obtained.
  • the novel compounds of the general formula (I) can be prepared analogously to the following examples. The examples described below are to be understood as illustrative of the invention without, however, limiting it.
  • reaction mixture is stirred for 1, 5 hours at -70 ° C, then allowed to come slowly to room temperature. It is diluted with dichloromethane and washed with 1 molar hydrochloric acid, sat. Sodium carbonate solution, water and sat. Washed sodium chloride solution. The organic phase is dried and evaporated to dryness. Yield: 30.80 g (96% of theory) [2- (5-Isopropyl-oxazol-2-yl) -ethyl] -carbamic acid benzyl ester:
  • N-hydroxy-propionamidine 2.00 g (22.70 mmol) of N-hydroxy-propionamidine are introduced into 10 ml of dimethylformamide and molecular sieve. 0.999 g (24.97 mmol) of sodium hydride (60% in mineral oil) are added. The mixture is stirred at 50 ° C. for 0.1 hours, then 5.00 g (24.60 mmol) of 3-tert-butylbenzene are added.
  • Butoxycarbonylamino-propionic acid methyl ester added in 20 ml of dimethylformamide. The reaction mixture is stirred for 3 hours at 50.degree. After cooling, 15 ml of water are added, filtered off with suction through CeNt. The 2 phases of the filtrate are separated, the organic phase is evaporated. The residue is purified by chromatography. Yield: 2.05 g (37% of theory)
  • the intermediate compounds (VIII.2) to (VIII.6) and also (VIII.7.1) can be prepared using the intermediate compound VI.1 and the suitable hydrazines.
  • the intermediate compound (IX.2), (IX.3) and (IX.7) can also be prepared using the intermediates (VIII.2), (VIII.3) and (VIII.7). Synthesis of the Intermediate Compound (Xl.1)
  • the intermediate compound (XXVII.2) can be obtained by using 3-isocyanatoacetic acid ethyl ester (XXV.2).
  • Method A XTerra® column, MS Ci 8 2.5 ⁇ m, 4.6 mm x 30 mm.
  • Method B Merck Chromolith TM SpeedROD RP-18e column, 4.6 mm x 50 mm.
  • Examples 119 and 121 to 179 can be represented.
  • Example 40 can be prepared using the corresponding amine.
  • Examples 180-184 can also be obtained by reacting the appropriate intermediates (IX) with the appropriate isocyanates.
  • Example 187 can be obtained using the appropriate beta-ketonitrile.
  • Residue purified by chromatography HPLC-MS. Corresponding fraction is lyophilized.
  • Examples 188-190 and 192-195 can be obtained by reacting intermediate compound (XXI.1) with the respectively suitable 1, 3-diketo compounds.
  • Example 196 can be obtained by reacting the intermediate compound (XXI.1) with the appropriate beta-ketoester. Synthesis of Example 208
  • Examples 198-207 and 209-215 can also be obtained by reacting intermediate compound (XXVII.1) with the appropriate hydrazines.
  • Examples 216-222 are obtained by reacting intermediate compound (XXVII.2) with the appropriate hydrazines in an analogous manner. Synthesis of Example 1
  • the exemplified compounds of formula (I) are characterized by an affinity for PI3 kinase, ie in the test by an IC 5 o value of less than 800 nmol / liter.
  • the compounds of formula (I) are characterized by a variety of therapeutic applications. Particularly noteworthy are those applications for which the compounds of the formula (I) according to the invention can preferably be used as PI3-kinase modulator due to their pharmaceutical activity.
  • diseases whose pathology involves activity of PI3 kinases, especially inflammatory and allergic diseases.
  • special are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastrointestinal tract, inflammatory diseases of the musculoskeletal system, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic disease states in which autoimmune reactions are involved or called kidney inflammations.
  • the treatment can be symptomatic, adaptive, curative or preventive.
  • Preferred respiratory diseases mentioned here would be chronic and / or obstructive respiratory diseases.
  • the compounds of the formula (I) according to the invention can, on the basis of their pharmacological properties, reduce the
  • Particularly preferred compounds of the invention are for the manufacture of a medicament for the treatment of chronic bronchitis, acute bronchitis, bronchitis due to bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive pulmonary disease (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or cystic fibrosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases such as Pulmonary fibrosis, asbestosis and silicosis and alveolitis; hyperresponsive respiratory tract, nasal polyps, pulmonary edema, e.g.
  • the compounds of the formula (I) for the treatment of diseases of the skin such as psoriasis, contact dermatitis, atopic dermatitis, alopecia areaa (circular hair loss), erythema exudativum multiforme (Stevens-Johnson syndrome), Dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria), lupus erythematosus, follicular and areal pyoderma, endogenous and exogenous acne, Acne rosacea as well as other inflammatory or allergic or proliferative skin diseases.
  • diseases of the skin such as psoriasis, contact dermatitis, atopic dermatitis, alopecia areaa (circular hair loss), erythema exudativum multiforme (Stevens-Johnson syndrome), Dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria
  • the compounds of formula (I) are useful for therapeutic use in inflammatory or allergic conditions involving autoimmune reactions, e.g. inflammatory bowel disease, e.g. Crohn's disease or ulcerative colitis; Diseases of the arthritis type, such as rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis.
  • autoimmune reactions e.g. inflammatory bowel disease, e.g. Crohn's disease or ulcerative colitis
  • Diseases of the arthritis type such as rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis.
  • Conjunctivitis conjunctivitis
  • conjunctivitis conjunctivitis
  • infections with fungi or bacteria e.g. by infections with fungi or bacteria, allergic conjunctivitis, irritant conjunctivitis, drug-induced conjunctivitis, keratitis, uveitis
  • Inflammatory or allergic conditions e.g. systemic lupus erythematosus, chronic hepatitis, nephritis, such as glomerulonephritis, interstitial nephritis, or idiopathic nephrotic syndrome.
  • diseases that can be treated with the same by the pharmacological activity of the compounds of formula (I) with a drug include toxic or septic shock syndromes, atherosclerosis, Friedrichohrentzün- fertil, (otitis media), hypertrophy of the heart, heart failure, stroke , Ischemic reperfusion injury or neurodegenerative diseases such as Parkinson's disease or Alzheimer's.
  • the compounds of the formula (I) can be used alone or in combination with other active compounds of the formula (I).
  • the compounds of the formula (I) can also be used in combination with W, where W is a pharmacokinetic is an active ingredient selected, for example, from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, H1 antihistamines, PAF antagonists and PI3 kinase inhibitors, preferably PI3- ⁇ -kinase inhibitors.
  • W is a pharmacokinetic is an active ingredient selected, for example, from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, H1 antihistamines, PAF antagonists and PI3 kinase inhibitors, preferably PI3- ⁇ -kinase inhibitors.
  • W represents a betamimetic combined with an active agent selected from the group consisting of anticholinergics, corticosteroids, PDE4 inhibitors, EGFR inhibitors and LTD4 antagonists
  • W represents an anticholinergic agent combined with an active agent selected from the group consisting of Betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors and LTD4 antagonists
  • W represents a corticosteroid combined with a drug selected from the group consisting of a PDE4 inhibitor, EGFR inhibitor and LTD4 antagonist
  • W represents a PDE4 inhibitor combined with an active agent selected from the group consisting of an EGFR inhibitor and LTD4 antagonist
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolertrol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol, meluadrine , Metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphoneterol, terbutaline, tiaramide, toluubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt Trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active ingredients.
  • the aforementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate , Benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodide and methanesulfonate are particularly preferred. Further named compounds are:
  • Preferred corticosteroids are compounds which are selected from the group consisting of prednisolone, prednisone, butixocortepionate, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, cronoside, rofleponide, dexamethasone, betamethasone, deflazacort, RPR -106541, NS-126, ST-26 and 6,9-Difluoro-17 - [(2-furanylcarbonyl) oxy] -11-hydroxy-16-methyl-3-oxo-androsta-1, 4-diene-17 carbothionic acid (S) -fluoromethyl ester
  • Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, suberobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmates, pivalates or even furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, suberobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmates, pivalates or even furoates.
  • compounds are preferably used which are selected from the group consisting of enprofylline, theophylline, roflumilast, A- riflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofylline, atizoram, D-4418, bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS - 613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-1 1294A, CI-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z- 15,370 and - N- (3,5-dichloro-1-oxopyridine-1-yl) -difluoromethoxy-S-cyclopropylmethoxybenzamide
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and
  • Preferred EGFR inhibitors are compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • compounds are preferably used which are selected from the group consisting of bromocriptine, cabergoline, alpha Dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and viozan, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p -toluolsulfonat.
  • H1 -Antihistaminika here are preferably compounds used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, Cexchlorpheniramin, pheniramine, doxylamine , Chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofluorate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • PAF antagonists are compounds which are selected from the group consisting of: 4- (2-chlorophenyl) -9-methyl-2- [3 (4-morpholinyl) -3-propanone-1-yl] -6H-thieno [3,2-f] -
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, Hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • PI3-kinase- ⁇ -inhibitors preferably compounds are used, which are selected from the group consisting of: IC87114, 2- (6-aminopurine-9-ylmethyl) -3- (2-chlorophenyl) -6,7-dimethoxy 3H-quinazolin-4-one; 2- (6-aminopurine-o-ylmethyl) -6-bromo-3- (2-chlorophenyl) -3H-quinazolin-4-one; 2- (6-aminopurine-o-ylmethyl) -3- (2-chlorophenyl) -7-fluoro-3H-quinazole in-4-one; 2- (6-aminopurine-9-ylmethyl) -6-chloro-3- (2-chlorophenyl) -3H-quinazolin-4-one; 2- (6-aminopurine-9-ylmethyl) -3- (2-chlorophenyl) -5-fluoro-3H-quina
  • the compounds according to the invention can be administered orally, transdermally, by inhalation, parenterally or sublingually.
  • the compounds of the invention are present as active ingredients in conventional dosage forms, for example in compositions consisting essentially of an inert pharmaceutical carrier and a effective dose of the active ingredient, such as, for example, tablets, dragees, capsules, wafers, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc.
  • An effective dose of the compounds according to the invention is between 0.1 and 5000, preferably between 1 and 500, more preferably between 5-300 mg / dose, between 0.001 and 50, preferably between 0.1 and 10 mg / dose in the case of intravenous, subcutaneous or intramuscular administration.
  • Inhalable administration forms are inhalable powders, metered-dose aerosols containing propellant or propellant-free inhalable solutions into consideration.
  • propellant-free inhalable solutions also includes concentrates or sterile, ready-to-use inhalable solutions.
  • suitable solutions for inhalation are those which contain from 0.01 to 1.0, preferably from 0.1 to 0.5% of active ingredient. It is likewise possible to use the compounds according to the invention as infusion solution, preferably in a physiological saline or broth.
  • the compounds according to the invention can be used alone or in combination with other active compounds according to the invention, if appropriate also in combination with other pharmacologically active substances.
  • Suitable application forms are, for example, tablets, capsules, suppositories, solutions, juices, emulsions or dispersible powders.
  • Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents for obtaining the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents for obtaining the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • the tablets can also consist of
  • Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers.
  • the Drageeülle to obtain a multi-layer depot effect, the excipients mentioned above in the tablets may be used.
  • Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, e.g. Flavorings such as vanillin or orange extract. They may also contain suspending aids or thickening agents, such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • a sweetener such as saccharin, cyclamate, glycerol or sugar
  • a taste-improving agent e.g. Flavorings such as vanillin or orange extract.
  • suspending aids or thickening agents such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • Injection solutions are prepared in the usual manner, e.g. with the addition of preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid prepared and filled into injection bottles or ampoules.
  • preservatives such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid prepared and filled into injection bottles or ampoules.
  • the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
  • inert carriers such as lactose or sorbitol
  • Suitable suppositories can be prepared, for example, by mixing with excipients intended for this purpose, such as neutral fats or polyethylene glycol or its derivatives.
  • Inhalable powders which can be used according to the invention may contain the active substance according to the invention either alone or in admixture with suitable physiologically acceptable excipients.
  • physiologically acceptable excipients can be used to prepare these inhalable powders according to the invention: monosaccharides (eg glucose or arabinose), disaccharides (eg lactose, sucrose, maltose), oligosaccharides and polysaccharides ( eg dextranes), polyalcohols (eg sorbitol, mannitol, xylitol), salts (eg sodium chloride, calcium carbonate) or mixtures of these auxiliaries with one another.
  • monosaccharides eg glucose or arabinose
  • disaccharides eg lactose, sucrose, maltose
  • oligosaccharides and polysaccharides eg dextranes
  • polyalcohols eg sorbitol, mannitol, xylitol
  • salts eg sodium chloride, calcium carbonate
  • Lactose most preferably lactose monohydrate, is used as adjuvant in the context of the invention.
  • the auxiliaries have a maximum average particle size of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, particularly preferably between 15 and 80 ⁇ m. If appropriate, it may seem appropriate to add finer excipient fractions having a mean particle size of 1 to 9 .mu.m to the abovementioned excipients. The latter finer excipients are also selected from the aforementioned group of usable excipients.
  • micronized active compounds according to the invention preferably having an average particle size of 0.5 to 10 .mu.m, more preferably from 1 to 5 .mu.m, mixed with the excipient mixture.
  • Methods for producing the inhalable powders according to the invention by grinding and micronizing as well as by final mixing of the constituents are known from the prior art.
  • inhalable powders according to the invention can be applied by means of inhalers known from the prior art.
  • Propellant gas-containing inhalation aerosols according to the invention can dissolve active substances according to the invention in propellant gas or contain them in dispersed form.
  • the propellant gases which can be used for the preparation of the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from the group consisting of hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the propellant gases mentioned above can be used alone or in mixtures thereof.
  • Particularly preferred propellants are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
  • the propellant-containing inhalation aerosols may also contain other ingredients such as cosolvents, stabilizers, surfactants, antioxidants, lubricants, and pH adjusters. All of these ingredients are known in the art.
  • MDIs metered dose inhalers
  • Suitable solvents for this purpose are aqueous or alcoholic, preferably ethanolic solutions.
  • the solvent may be water only or it may be a mixture of water and ethanol.
  • the relative proportion of ethanol to water is not limited, but the maximum limit is preferably up to 70% by volume, in particular up to 60% by volume and more preferably up to 30% by volume. The remaining volume percentages are filled up with water.
  • the solutions or suspensions containing the active compound according to the invention are adjusted to a pH of from 2 to 7, preferably from 2 to 5, with suitable acids.
  • acids selected from inorganic or organic acids can be used.
  • inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and / or phosphoric acid.
  • particularly suitable organic acids are: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid and sulfuric acid. It is also possible to use the acids which already form an acid addition salt with one of the active substances.
  • organic acids ascorbic acid, fumaric acid and citric acid are preferred.
  • mixtures of the abovementioned acids in particular in the case of acids which, in addition to their acidification properties, also possess other properties, for example as flavorings, antioxidants or complexing agents, for example citric acid or ascorbic acid.
  • Hydrochloric acid is particularly preferably used according to the invention for adjusting the pH.
  • formulations may optionally be dispensed with the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as a stabilizer or complexing agent.
  • EDTA editic acid
  • sodium edetate sodium edetate
  • other embodiments include this compound (s).
  • the content based on sodium edetate is below 100 mg / 100 ml, preferably below 50 mg / 100 ml, particularly preferably below 20 mg / 100 ml.
  • those inhalation solutions are preferred in which the content of sodium edetate is 0 to 10 mg / 100 ml.
  • Co-solvents and / or other auxiliaries can be added to the propellant-free inhalable solutions.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, for example alcohols, in particular isopropyl alcohol, Glycols - especially propylene glycol, polyethylene glycol, polypropylene glycol, glycol ethers, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • auxiliaries and additives is meant in this context any pharmacologically acceptable substance which is not an active substance but which can be formulated together with the active ingredient (s) in the pharmacologically suitable solvent in order to improve the qualitative properties of the active ingredient formulation.
  • auxiliaries and additives include, for example, surfactants, such as soybean lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone other stabilizers, complexing agents, antioxidants and / or preservatives that ensure or prolong the useful life of the finished drug formulation, flavorings, vitamins and / or other additives known in the art.
  • the additives also include pharmacologically acceptable salts such as sodium chloride as isotonants.
  • Preferred excipients include antioxidants, such as ascorbic acid, if not already used to adjust the pH, vitamin A, vitamin E, tocopherols, and similar vitamins or provitamins found in the human organism.
  • Preservatives may be used to protect the formulation from contamination by germs. Suitable preservatives are those known in the art, in particular cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • the abovementioned preservatives are preferably present in concentrations of up to 50 mg / 100 ml, more preferably between 5 and 20 mg / 100 ml.
  • preferred formulations contain water and the active ingredient according to the invention only benzalkonium chloride and sodium edetate. In another preferred embodiment, sodium edetate is dispensed with.
  • a therapeutically effective daily dose is between 1 and 2000 mg, preferably 10-500 mg per adult
  • the finely ground active substance, lactose and part of the corn starch are mixed together.
  • the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried.
  • the granules, the remainder of the corn starch and the magnesium stearate are sieved and mixed together.
  • the mixture is compressed into tablets of suitable shape and size.
  • the finely ground active substance, a part of the maize starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the remainder of the maize starch and water to a granulate which is dried and sieved. To this is added the sodium carboxymethyl starch and the magnesium stearate, mixed and pressed the mixture into tablets of suitable size.
  • the active ingredient, corn starch, lactose and polyvinylpyrrolidone are mixed well and moistened with water.
  • the moist mass is forced through a sieve with 1 mm mesh size, dried at about 45 ° C and then strikes the granules through the same sieve.
  • curved tablet cores having a diameter of 6 mm are pressed on a tableting machine.
  • the coated dragee cores are coated in a known manner with a layer consisting essentially of sugar and talcum.
  • the finished dragees are polished with wax.
  • Substance and cornstarch are mixed and moistened with water.
  • the moist mass is sieved and dried.
  • the dry granules are sieved and mixed with magnesium stearate.
  • the final mixture is filled into hard gelatine capsules size 1.
  • Aqua pro inj. 5 ml The active ingredient is dissolved at its own pH or optionally at pH 5.5 to 6.5 in water and treated with sodium chloride as isotonic. The resulting solution is filtered pyrogen-free and the filtrate is filled under aseptic conditions in ampoules, which are then sterilized and sealed.
  • the vials contain 5 mg, 25 mg and 50 mg active ingredient.
  • the hard fat is melted.
  • the ground active substance is dispersed homogeneously. It is cooled to 38 ° C and poured into slightly pre-cooled suppository molds
  • HFA134A HFA227 2: 1 99.1% by weight
  • the suspension is filled in a conventional aerosol container with metering valve. Per actuation preferably 50 ul suspension are delivered. If desired, the active ingredient can also be metered in higher
  • the preparation of the solution is carried out in a conventional manner by mixing the individual components.
  • the preparation of the inhalable powder is carried out in the usual manner by mixing the individual components.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07727387A 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren Withdrawn EP2007382A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07727387A EP2007382A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06112298 2006-04-06
EP07727387A EP2007382A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren
PCT/EP2007/052914 WO2007115931A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren

Publications (1)

Publication Number Publication Date
EP2007382A1 true EP2007382A1 (de) 2008-12-31

Family

ID=36764026

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07727387A Withdrawn EP2007382A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren

Country Status (15)

Country Link
US (1) US7517995B2 (enExample)
EP (1) EP2007382A1 (enExample)
JP (1) JP2009532415A (enExample)
KR (1) KR20080111118A (enExample)
CN (1) CN101460167A (enExample)
AR (1) AR060267A1 (enExample)
AU (1) AU2007236045A1 (enExample)
BR (1) BRPI0710306A2 (enExample)
CA (1) CA2647292A1 (enExample)
IL (1) IL194494A0 (enExample)
MX (1) MX2008012534A (enExample)
RU (1) RU2008143547A (enExample)
TW (1) TW200806679A (enExample)
WO (1) WO2007115931A1 (enExample)
ZA (1) ZA200807713B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
JPWO2010024258A1 (ja) * 2008-08-29 2012-01-26 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体
AU2009299927B2 (en) 2008-10-01 2013-05-30 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
US8653097B2 (en) 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
TW201103943A (en) * 2009-04-27 2011-02-01 Shionogi & Co Urea derivative having pi3k inhibitory activity
KR20120046723A (ko) 2009-07-02 2012-05-10 노파르티스 아게 Ｐｉ３ｋ 억제제로서 유용한 2-카르복스아미드 시클로아미노 우레아
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
JP2014114212A (ja) * 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
SI2838900T1 (sl) * 2012-04-17 2019-10-30 Gilead Sciences Inc Spojine in postopki za protivirusno zdravljenje
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236698A1 (en) 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
US7846925B2 (en) 2002-07-10 2010-12-07 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
PT2042504E (pt) 2002-09-30 2011-09-07 Bayer Schering Pharma Ag Derivados da azolepirimidina fundida
EP1557661A1 (en) 2002-10-30 2005-07-27 Toppan Printing Co., Ltd. Inspection apparatus of wiring pattern, inspection method, detection apparatus, detection method
WO2004052373A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003303231A1 (en) 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
RU2006100484A (ru) 2003-06-13 2006-06-10 Центарис ГмбХ, Германи (DE) Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
AU2005293607A1 (en) 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007115931A1 *

Also Published As

Publication number Publication date
WO2007115931A8 (de) 2008-06-12
WO2007115931A1 (de) 2007-10-18
KR20080111118A (ko) 2008-12-22
JP2009532415A (ja) 2009-09-10
ZA200807713B (en) 2009-08-26
AU2007236045A1 (en) 2007-10-18
AR060267A1 (es) 2008-06-04
CN101460167A (zh) 2009-06-17
CA2647292A1 (en) 2007-10-18
RU2008143547A (ru) 2010-05-20
BRPI0710306A2 (pt) 2011-08-09
IL194494A0 (en) 2009-08-03
MX2008012534A (es) 2008-10-10
US20070238730A1 (en) 2007-10-11
US7517995B2 (en) 2009-04-14
TW200806679A (en) 2008-02-01

Similar Documents

Publication Publication Date Title
EP2007382A1 (de) Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren
WO2007115933A1 (de) Thiazolyl-dihydro-indazole
EP2007772A1 (de) Thiazolyl-dihydro-chinazoline
EP2205609B1 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
EP2018386A1 (de) Thiazolyl-dihydro-indazole
EP2313406B1 (de) 4-dimethylaminophenyl-substituierte napththyridine und ihre verwendung als arzneimittel
EP1802636A1 (de) Pi3-kinasen
DE102005019201A1 (de) Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
EP2018385B1 (de) Thiazolyl-dihydro-quinazoline
DE102005005813A1 (de) PI3-Kinasen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PRAGST, INGO

Inventor name: PIEPER, MICHAEL

Inventor name: ERB, KLAUS

Inventor name: SCHEUERER, STEFAN

Inventor name: HOFFMANN, MATTHIAS

Inventor name: GRAUERT, MATTHIAS

Inventor name: BRANDL, TRIXI

Inventor name: PAUTSCH, ALEXANDER

Inventor name: JOERGENSEN, ANNE T.

Inventor name: HOENKE, CHRISTOPH

Inventor name: MAIER, UDO

Inventor name: BREITFELDER, STEFFEN

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110921